Table 3.
Competing-risks regression model (N = 19 080) for factors associated with mortality in the first three months of antiretroviral therapy
| Variable | n | Sub-hazard ratio (95% CI) | p-Value |
|---|---|---|---|
| Sex | |||
| Non-pregnant female | 11 523 | 1 | |
| Pregnant female | 1383 | 0.23 (0.12-0.45) | <0.001 |
| Male | 6174 | 1.48 (1.28-1.70) | <0.001 |
| Age | |||
| 16-24 | 2289 | 0.70 (0.53-0.93) | 0.014 |
| 25-34 | 7598 | 1 | |
| 35-44 | 5536 | 0.91 (0.77-1.06) | 0.225 |
| 45-54 | 2669 | 1.09 (0.89-1.32) | 0.412 |
| ≥55 | 988 | 1.11 (0.83-1.49) | 0.467 |
| Baseline CD4+ cell count, cells/μL | |||
| <50 | 3365 | 4.25 (3.23-5.60) | <0.001 |
| 50-200 | 11 175 | 1.46 (1.11-1.91) | 0.006 |
| 201-350 | 3969 | 1 | |
| >350 | 571 | 0.74 (0.38-1.45) | 0.384 |
| Concurrent TB diseasea | |||
| No | 13 943 | 1 | |
| Yes | 3331 | 1.08 (0.92-1.28) | 0.357 |
| Missing | 1806 | 1.19 (0.96-1.48) | 0.121 |
| Time period of ART initiation | |||
| 2004-5 | 280 | 1.37 (0.87-2.15) | 0.121 |
| 2005-6 | 907 | 0.88 (0.63-1.24) | 0.470 |
| 2006-7 | 1408 | 1.18 (0.91-1.54) | 0.204 |
| 2007-8 | 2754 | 0.84 (0.66-1.06) | 0.139 |
| 2008-9 | 3079 | 1 | |
| 2009-10 | 3159 | 1.27 (1.03-1.58) | 0.027 |
| 2010-11 | 3294 | 1.16 (0.93-1.44) | 0.191 |
| 2011-12 | 4199 | 0.54 (0.41-0.71) | <0.001 |
CI, confidence interval
a
Concurrent TB disease was TB disease treated at the time of ART initiation